This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.
The lancet. Diabetes & endocrinology, 10(12), 859-868
Citation
Haqq, Andrea M; Chung, Wendy K; Dollfus, Hélène; Haws, Robert M; Martos-Moreno, Gabriel Á; Poitou, Christine; Yanovski, Jack A; Mittleman, Robert S; Yuan, Guojun; Forsythe, Elizabeth; Clément, Karine; Argente, Jesús. (2022). Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.. The lancet. Diabetes & endocrinology, 10(12), 859-868. https://doi.org/10.1016/S2213-8587(22)00277-7